Beef­ing up its res­pi­ra­to­ry pipeline, Glax­o­SmithK­line bags J&J drug in $230M deal

Glax­o­SmithK­line has found a new ther­a­py to add to its big pipeline of res­pi­ra­to­ry drugs. The UK-based phar­ma group in-li­censed J&J’s CN­TO 7160, an an­ti-IL-33R mon­o­clon­al an­ti­body now in Phase I. J&J stands to get $230 mil­lion in an up­front plus a slate of mile­stones, which weren’t bro­ken out in the state­ment.

The drug blocks in­ter­leukin-33 from bind­ing to the ST2 re­cep­tor, a bi­o­log­ic step that plays a role with in­flam­ma­to­ry cells like neu­trophils and eosinophils, a big fo­cus in asth­ma, which GSK has cen­tered on for years now.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.